Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).

MLA

Wasel, Norman, et al. “Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).” Dermatology and Therapy, vol. 10, no. 4, Aug. 2020, pp. 663–70. EBSCOhost, https://doi.org/10.1007/s13555-020-00383-x.

APA

Wasel, N., Thaçi, D., French, L. E., Conrad, C., Dutronc, Y., Gallo, G., Berggren, L., & Lacour, J.-P. (2020). Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatology and Therapy, 10(4), 663–670. https://doi.org/10.1007/s13555-020-00383-x

Chicago

Wasel, Norman, Diamant Thaçi, Lars E French, Curdin Conrad, Yves Dutronc, Gaia Gallo, Lovisa Berggren, and Jean-Philippe Lacour. 2020. “Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).” Dermatology and Therapy 10 (4): 663–70. doi:10.1007/s13555-020-00383-x.